Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years

Annals of Oncology

Volumn 27, Issue , 2016, Pages i1-i3

  Kaye, S B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Homologous recombination deficiency; Poly(ADP)ribase polymerase

Indexed keywords

BEVACIZUMAB; CEDIRANIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RECURRENCE; DRUG APPROVAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; GENE MUTATION; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TUMOR SUPPRESSOR GENE; FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; OVARY TUMOR; RECOMBINATION REPAIR; TOTAL QUALITY MANAGEMENT;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; QUALITY IMPROVEMENT; RECOMBINATIONAL DNA REPAIR;

EID: 84966297424     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw082     Document Type: Article

References (26)

1. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
2. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434: 913-917.
3. Plummer R, Jones C, Middleton M et al. Phase I study of the PARP inhibitor, AGO14699 in combination with temozolomide in patients with advanced solid tumours. Clin Cancer Res 2008; 14: 7917-7923.
4. Fong PC, Boss DS, Yap TA et al. Inhibition of poly (ADP-ribose) polymerase in tumours from BRCA mutation carriers. NEJM 2009; 361: 123-134.
5. Fong P, Yap TA, Boss DS et al. Poly (ADP-ribose) polymerase inhibition. Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2159.
6. Audeh MW, Carmichael J, Penson RT et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA 2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
7. Kaye SB, Lubinski J, Matulonis U et al. A phase II, open-label, randomized, multicentre study to compare the efficacy and safety of olaparib, a poly(ADPribose) polymerase (PARP) inhibitor, and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30(4): 372-379.
8. Safra T, Borgato L, Nicoletto M et al. BRCA mutation and determinant of outcome in women with recurrent epithelial ovarian cancer, treated with pegylated liposomal doxorubicin. Mol Cancer Ther 2011; 10: 2000-2007.
9. FDA News Release 19th December 2014.
10. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-250.
11. Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian carcinoma. Nature 2011; 474: 609-615.
12. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer. A phase 2 multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.
13. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2011; 366: 1382-1392.
14. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer: a pre-planned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-861.
15. Sandhu SK, Schelman WR, Wilding G et al. The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase I dose-escalation trial. Lancet Oncol 2013; 14: 882-892.
16. Swisher E, Brenton J, Kaufman S, Oza A et al. 215 Updated clinical and preliminary correlative results of ARIEL2 a phase II study to identify ovarian cancer patients likely to respond to rucaparib. Eur J Cancer 2014; 50: p73.
17. Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors. Cancer Discov 2013; 3: 20-23.
18. Ang JE, Gourley C, Powell CB et al. Efficacy of chemotherapy in BRCA 1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multiinstitutional study. Clin Cancer Res 2012; 19: 5485-5493.
19. Haluska P, Timms KM, AlHilli M et al. Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer. Eur J Cancer 2014; 50 (Suppl 6): 72-73.
20. McNeish I, Oza A, Coleman R et al. Results of ARIEL 2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumour genetic analysis. J Clin Onc 2015; 33(suppl): abstr 5508.
21. Oza A, Cibula D, Oaknin A et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16: 87-97.
22. Chan N, Bristow RG. 'Contextual' synthetic lethality and/or loss of heterozygosity: tumour hypoxia and modification of DNA repair. Clin Cancer Res 2010; 16: 4553-4560.
23. Ibrahim YH, Garcia-Garcia C, Serra V et al. PI3K inhibition impairs BRCA1/2 expression and sensitises BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2: 1036-1047.
24. Aghajanian C, Blank S, Goff B et al. OCEANS: a randomised double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer. J Clin Oncol 2013; 30: 2039-2045.
25. Liu J, Barry WT, Birrer M et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase II study. Lancet Oncol 2014; 15: 1207-1214.
26. Dean E, Middleton M, Pwint T et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012; 106: 468-474.